GlassScriptPhysician profile
Chris P Penning
NPI 1679555734
$6,977.81
in general payments reported to CMS, 2019-2025
46 companies · $727 in 2025
The $727 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $1,048 · 2021: $1,093 · 2022: $1,068 · 2023: $1,181 · 2024: $1,075 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,391.49 | 2019-2025 | |
| Novo Nordisk INC | $845.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $750.83 | 2019-2025 | Farxiga, Breztri, Flumist Quadrivalent |
| Lilly USA, LLC | $467.69 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $294.93 | 2022-2025 | |
| Amarin Pharma, INC. | $210.95 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $209.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $203.69 | 2019-2021 | |
| Corium, LLC | $203.16 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $197.69 | 2020-2021 | |
| Glaxosmithkline, LLC. | $166.59 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Allergan, INC. | $155.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.95 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $121.30 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $111.52 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Penning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.